Enabling Next-Generation Biotherapeutics
Making innovative biotherapeutics available for patients in need.Perspix Biotech is creating next-generation biotherapeutics for patients with cancer by leapfrogging traditional drug discovery and development approaches. We aim to radically accelerate the technical development of next-generation biological drug modalities through a truly digitally transformed discovery platform. This will significantly reduce development times and costs – making innovative biotherapeutics available for patients in need.
Focus on multi-specific antibodies
Multi-specific antibody therapeutics are emerging as powerful treatment options for complex, multifactorial illnesses in particular cancer. They are engineered to combine the functional activities of two or more monoclonal antibodies (mAbs) into one molecule to address multiple disease targets simultaneously.
However, due to the inherent complexity of the design process, the development of multi-specific antibody therapeutics has been time-consuming and expensive with low probability of success to reach market.
Now it is time for a change.
Through its innovative platform, Perspix is opening new ways for cost-efficient and fast discovery of next-generation multi-specific antibodies by applying advanced digital approaches all along a fully automated value chain.
Enabling Next-Generation Biotherapeutics
Making innovative biotherapeutics available for patients in need.Perspix Biotech is creating next-generation biotherapeutics for patients with cancer by leapfrogging traditional drug discovery and development approaches. We aim to radically accelerate the technical development of next-generation biological drug modalities through a truly digitally transformed discovery platform. This will significantly reduce development times and costs – making innovative biotherapeutics available for patients in need.
Focus on multi-specific antibodies
Multi-specific antibody therapeutics are emerging as powerful treatment options for complex, multifactorial illnesses in particular cancer. They are engineered to combine the functional activities of two or more monoclonal antibodies (mAbs) into one molecule to address multiple disease targets simultaneously.
However, due to the inherent complexity of the design process, the development of multi-specific antibody therapeutics has been time-consuming and expensive with low probability of success to reach market.
Now it is time for a change.
Through its innovative platform, Perspix is opening new ways for cost-efficient and fast discovery of next-generation multi-specific antibodies by applying advanced digital approaches all along a fully automated value chain.
Now it is time for change
Copyright 2022 Perspix Biotech | All rights reserved
Copyright 2022 Perspix Biotech | All rights reserved